Navigation Links
Innocoll Enters CollaGUARD® Distribution Partnership With Flynn Pharma Ltd in the UK and Inresa Arzneimittel GmbH in Germany

ASHBURN, Va., Feb. 1, 2012 /PRNewswire/ -- Innocoll Inc. announced it has entered into a License and Distribution Agreement with Flynn Pharma Ltd. in the United Kingdom and with Inresa Arzneimittel GmbH in Germany for CollaGUARD surgical adhesion barrier for the prevention of postoperative adhesions following abdominal and pelvic surgery. 

Dr. Michael Myers, President and CEO stated, "We are pleased to announce these partnerships for two of the key markets in the EU and we look forward to a successful launch of this important product."   

David Walters, Director of Flynn and Inresa commented, "We are delighted to be working with Innocoll on this innovative product which is consistent with, and complementary to, our model of adding products for the secondary healthcare markets." 

About CollaGUARD®
CollaGUARD is a transparent bioresorbable film of 100% type I collagen developed using Innocoll's proprietary CollaFilm technology. It is approved in Europe for the prevention of postoperative adhesions in patients undergoing abdominopelvic laparotomy or laparoscopy.  When tested in vivo, CollaGUARD increased the probability of remaining adhesion-free by more than six fold (< 0.001) and significantly reduced the extent and severity of adhesions (< 0.001).

CollaGUARD has been designed and engineered with a unique combination of features for optimal handling, ease-of-use, and anti-adhesion performance. It is highly stable at room temperature and does not require any advanced preparation before use. The product is non-tacky and can be easily rolled for insertion through a trocar when implanted laparoscopically. CollaGUARD is available in a wide variety of sizes up to 20 x 30 cm; it may be cut and sutured if required and therefore used efficiently across a broad range of surgeries. 

Innocoll has entered into distribution partnerships for CollaGUARD in over 23 countries.  For more information please visit

About Postoperative Adhesions
Postoperative adhesions are abnormal fibrous connections that can form between any apposing internal organ and serous membrane as a natural consequence of abdominopelvic surgery. Adhesions occur in almost 95% of laparotomies and may lead to serious complications such as intestinal obstruction, secondary female infertility, and chronic abdominal or pelvic pain. More than 30% of patients who undergo open gynecologic or general surgery are readmitted within 10 years for disorders that are considered directly or potentially related to adhesions, with an average of 2 readmissions per patient. In the United States, there are approximately 350,000 hospitalizations annually for adhesiolysis following gynecologic or abdominal surgery, which account for almost 1 million inpatient days at a cost of $2.3 billion. Even for patients without complications, adhesions originating from a previous surgery can present significant surgical challenges and additional morbidity risks in subsequent operations.

About Flynn Pharma.

Flynn Pharma Limited is a specialty pharmaceutical company focused on acquiring and commercializing proprietary products in secondary healthcare and related markets.  Flynn's goal is to be the foremost European provider of specialty products in targeted and underserved therapeutic categories. In the last few years, Flynn has been restructured and financed to pursue an aggressive and rapid growth strategy in these sectors, offering superior customer service and value growth for our shareholders.

For additional information about Flynn visit the Company's website at

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm, DermaSil™, CollaPressTM and Liquicoll®. Approved products based on the Company's technologies include: Collatamp® G, Septocoll®, CollaGUARD, Collieva®, CollaCare®, Collexa®, Zorpreva™, and LidoColl®.

Other products in clinical and regulatory development include: CollaRx Gentamicin Surgical Implant in phase 3 for prevention of surgical wound infections, Cogenzia in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, and Xaracoll in phase 3 for the management of post-operative pain. For more information, please visit

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Innocoll Enters Partnership with Merus Labs in Canada for the Distribution of CollaGUARD
2. Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD
3. Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier
4. Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products
5. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
6. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
7. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
8. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
10. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
11. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
Post Your Comments:
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Japanese therapeutic drug monitoring market, ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the German ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Therapeutic Drug Monitoring ... Forecasts, Competitive Intelligence, Emerging Opportunities"  report ... ) has announced the addition ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New Drug ... so important to this key industry segment, Regis Technologies has decided to sponsor and ... 4th at 11am EST. , Federal law does not allow new drugs to cross ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ... importance to the medical schools of the future. To reach an audience of ... the 2015 ChangeMedEd conference in Chicago, organized by the American Medical Association. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce their strategic partnership at the Radiological Society of North America (RSNA) ... Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced their ...
(Date:11/30/2015)... ... November 30, 2015 , ... Bayco Products, Inc today announced the introduction of three Nightstick® brand ... choice of three different colors; red ( NSP-1632 ), yellow ( NSP-1634 ) and blue ... hours in constant-on mode, or 27 hours in blinking strobe mode using a fresh set ...
(Date:11/29/2015)... ... November 30, 2015 , ... The Cyber Monday deal is a deep 40% or more discount ... to get gifts for the skin care lover in your circle. Each Christmas, Sublime ... This year, the 3 serums are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking stuffers ...
Breaking Medicine News(10 mins):